– Profit Attributable to Shareholders Increases to HK$301.6 Million – While Revenue Holds Firm at HK$1.57 Billion – Resilient Performance across Core Therapeutic Areas – amid Normalising Seasonal Demand KEY…
– Profit from Continuing Operations Surges 43.1% to HK$300.8 million – Sustained Momentum by Capturing Healthcare Trends – Solid Financial Strength to Fuel Future Growth KEY HIGHLIGHTS – Revenue up…
Profit Attributable to Shareholders Increases by Over 70% Declares Interim Dividend of HK2.8 Cents Per Share Solid Growth Momentum Bolstered by Healthcare Demand Jacobson Pharma Corporation Limited (Jacobson Pharma or…
Declares Final Dividend of HK1.5 Cents Per Share Resilient Performance Albeit Market Challenges Jacobson Pharma Corporation Limited (Jacobson Pharma or the Company; Stock Code: 2633), a leading company engaging in…
Jacobson Pharma Corporation Limited (“Jacobson Pharma” or the “Company”; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines,…
Jacobson Pharma Corporation Limited (“Jacobson Pharma” or “the Group”; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale of essential medicines and branded healthcare…
Jacobson Pharma Corporation Limited (“Jacobson Pharma” or the “Company”; Stock Code: 2633), a leading company engaging in research, development, production, marketing and sale of generic drugs and proprietary medicines, today…
Profit Attributable to Shareholders Increased by 23.9% to a Record High of HK$250.6 Million; Total Dividend Up 18.4% to HK4.5 Cents per Share Jacobson Pharma Corporation Limited (“Jacobson Pharma” or…
Expects to Record Over 20% Increase in Profit Attributable to Shareholders Jacobson Pharma Corporation Limited (“Jacobson Pharma” or the “Company”; Stock Code: 2633), a leading company engaging in the research,…
